Social investing, though not yet fully mainstream, has the potential to obtain such status. Questions relating to the future of social investing include the following. (1) What properly falls within the ambit of social investing? Assuming that no single definition of social responsibility is feasible, what then are the limits? (2) What do we need to know about investor psychology concerning social investing? What motivates people to buy socially screened investments and why do they sometimes act inconsistently? (3) How can we improve the measures of social performance? Is it possible to develop GAAP and GAAS equivalents for social reporting? (4) Should social reports by firms be audited? If so, how? (5) What sorts of public policies are necessary to support the social screening of investments? 相似文献
This paper provides a solution to the problem of estimating a joint distribution using the associated marginal distributions and a related joint distribution. The particular application we have in mind is estimating joint distributions of demographic characteristics corresponding to market areas for individual retail stores. Marginal distributions are generally available at the census tract level, but joint distributions are only available for Metropolitan Statistical Areas which are generally much larger than the market for a single retail store. Joint distributions over demographics are an important input into mixed logit demand models for aggregate data. Market shares that vary systematically with demographics are essential for relieving the restrictions imposed by the Independence from Irrelevant Alternative property of the logit model.We approach this problem by formulating a parametric function that incorporates both the city-wide joint distributional information and marginal information specific to the retail stores market area. To estimate the function, we form moment conditions equating the moments of the parametric function to observed data, and we input these into a GMM objective. In one of our illustrations we use four marginal demographic distributions from each of eight stores in Dominicks Finer Foods data archive to estimate a four dimensional joint distribution for each store. Our results show that our GMM approach produces estimated joint distributions that differ substantially from the product of marginal distributions and emit marginals that closely match the observed marginal distributions. Mixed logit demand estimates are also presented which show the estimates to be sensitive to the formulation of the demographics distribution.The views expressed are not purported to reflect those of the United States Department of Justice 相似文献
Knee cartilage damage is a common cause of referral for orthopedic surgery. Treatment aims to reduce pain and symptoms by repairing cartilage. Microfracture, the current standard of care, yields good short-term clinical outcomes; however, treatment might fail after 2–3 years. A Chitosan-Beta glycerolphosphate-based medical device (BST-CarGel) is used as an adjunct to microfracture and demonstrates improvements in quantity and quality of repaired tissue, potentially reducing the risk of treatment failure. This study aimed to establish the economic value of BST-CarGel vs microfracture alone in knee cartilage repair from the societal perspective, using Germany as the reference market.
Methods:
A decision tree with a 20-year time-horizon was constructed, in which undesirable clinical events were inferred following initial surgery. These events consisted of pain management, surgery, and total knee replacement. Clinical outcomes were taken from the pivotal clinical trial, supplemented by other literature. Data and assumptions were validated by a Delphi panel. All relevant resource use and costs for procedures and events were considered.
Results:
In a group of patients with all lesion sizes, the model inferred that BST-CarGel yields a positive return on investment at year 4 (with 20-year cumulative cost savings of €6448). Reducing the incremental risk of treatment failure gap between the device and microfracture by 25–50% does not alter this conclusion. Cost savings are greatest for patients with large lesions; results for patients with small lesions are more modest.
Limitations:
Clinical evidence for microfracture and other interventions varies in quality. Comparative long-term data are lacking. The comparison is limited to microfracture and looks only at costs without considering quality-of-life.
Conclusion:
BST-CarGel potentially represents a cost-saving alternative for patients with knee cartilage injury by reducing the risk of clinical events through regeneration of chondral tissue with hyaline characteristics. Since the burden of this condition is high, both to the patient and society, an effective and economically viable alternative is of importance. 相似文献